Evidence map›Paper›PMID 38939343›Full record

ArticleFrontiers in oncology2024

No advantage of antimicrobial prophylaxis in AML/MDS/CMML patients treated with azacitidine-a prospective multicenter study by the Polish Adult Leukemia Group.

Krzysztof Mądry, Karol Lis, Elzbieta Sienkiewicz, Joanna Drozd-Sokołowska, Przemysław Biecek, Oktawia Sośnia, Aleksandra Gołos, Magdalena Olszewska-Szopa, Agata Obara, Zuzanna Walkowiak and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Krzysztof MądryDepartment of Hematology, Transplantation and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
Karol LisDepartment of Hematology, Transplantation and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
Elzbieta SienkiewiczFaculty of Mathematics and Information Science, Warsaw University of Technology, Warsaw, Poland.
Joanna Drozd-SokołowskaDepartment of Hematology, Transplantation and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
Przemysław BiecekFaculty of Mathematics and Information Science, Warsaw University of Technology, Warsaw, Poland.
Oktawia SośniaDepartment of Hematology, Institute of Hematology and Transfusiology, Warsaw, Poland.
Aleksandra GołosDepartment of Hematology, Medical University Łódź, Łodz, Poland.
Magdalena Olszewska-SzopaDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wrocław, Poland.
Agata ObaraDepartment of Hematology, Holycross Cancer Center, Kielce, Poland.
Zuzanna WalkowiakDepartment of Hematology, Multi-Specialist Hospital Gorzów Wielkopolski, Faculty of Medicine and Health Science, University of Zielona Góra, Gorzów Wielkopolski, Poland.
Joanna ŚciesińskaDepartment of Hematology and Transplantology, Medical University of Gdansk, Gdańsk, Poland.
Edyta SuboczDepartment of Hematology, Warmian-Masurian Cancer Center of the Ministry of the Interior and Administration's Hospital, Olsztyn, Poland.
Aleksandra ButrymDepartment of Cancer Prevention and Therapy, Wroclaw Medical University, Wrocław, Poland.
Rafał MachowiczDepartment of Hematology, Transplantation and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
Katarzyna BudziszewskaDepartment of Hematology, Institute of Hematology and Transfusiology, Warsaw, Poland.
Grzegorz BasakDepartment of Hematology, Transplantation and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Infections represent one of the most frequent causes of death of higher-risk MDS patients, as reported previously also by our group. Azacitidine Infection Risk Model (AIR), based on red blood cell (RBC) transfusion dependency, neutropenia <0.8 × 10 Methods: The prospective non-intervention study aimed to identify factors predisposing to infection, validate the AIR score, and assess the impact of antimicrobial prophylaxis on the outcome of azacitidine-treated MDS/AML and CMML patients. Results: We collected data on 307 patients, 57.6 % males, treated with azacitidine: AML (37.8%), MDS (55.0%), and CMML (7.1%). The median age at azacitidine treatment commencement was 71 (range, 18-95) years. 200 (65%) patients were assigned to higher risk AIR group. Antibacterial, antifungal, and antiviral prophylaxis was used in 66.0%, 29.3%, and 25.7% of patients, respectively. In total, 169 infectious episodes (IE) were recorded in 118 (38.4%) patients within the first three azacitidine cycles. In a multivariate analysis ECOG status, RBC transfusion dependency, IPSS-R score, and CRP concentration were statistically significant for infection development ( Discussion: The AIR Model effectively discriminates infection-risk patients during azacitidine treatment. Antimicrobial prophylaxis does not decrease the infection rate.

Indexed as

acute myeloid leukemiaazacitidinechronic myelomonocytic leukemiainfectioninfection preventionmyelodysplastic syndromes

Identifiers

PMID38939343
PMCPMC11208299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.